481 related articles for article (PubMed ID: 29556358)
1. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
Dong JK; Lei HM; Liang Q; Tang YB; Zhou Y; Wang Y; Zhang S; Li WB; Tong Y; Zhuang G; Zhang L; Chen HZ; Zhu L; Shen Y
Theranostics; 2018; 8(7):1808-1823. PubMed ID: 29556358
[TBL] [Abstract][Full Text] [Related]
2. Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas.
Lei HM; Zhang KR; Wang CH; Wang Y; Zhuang GL; Lu LM; Zhang J; Shen Y; Chen HZ; Zhu L
Theranostics; 2019; 9(24):7122-7139. PubMed ID: 31695757
[No Abstract] [Full Text] [Related]
3. Resistant to Targeted Therapy - Aim for Metabolic Liabilities.
Queiroz AL; Vakifahmetoglu-Norberg H; Norberg E
Theranostics; 2018; 8(7):2061-2063. PubMed ID: 29569651
[TBL] [Abstract][Full Text] [Related]
4. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
6. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
7. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
Chmielecki J; Pietanza MC; Aftab D; Shen R; Zhao Z; Chen X; Hutchinson K; Viale A; Kris MG; Stout T; Miller V; Rizvi N; Pao W
J Thorac Oncol; 2012 Feb; 7(2):434-42. PubMed ID: 22173702
[TBL] [Abstract][Full Text] [Related]
8. A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma.
Liang Q; Gong M; Zou JH; Luo MY; Jiang LL; Wang C; Shen NX; Zhang MC; Xu L; Lei HM; Zhang KR; Zhang R; Zhuang G; Zhu L; Chen HZ; Zhou L; Shen Y
Drug Resist Updat; 2023 May; 68():100957. PubMed ID: 36990047
[TBL] [Abstract][Full Text] [Related]
9. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
Cardona AF; Arrieta O; Zapata MI; Rojas L; Wills B; Reguart N; Karachaliou N; Carranza H; Vargas C; Otero J; Archila P; Martín C; Corrales L; Cuello M; Ortiz C; Pino LE; Rosell R; Zatarain-Barrón ZL;
Target Oncol; 2017 Aug; 12(4):513-523. PubMed ID: 28620690
[TBL] [Abstract][Full Text] [Related]
10. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
11. An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
Nihira K; Miki Y; Iida S; Narumi S; Ono K; Iwabuchi E; Ise K; Mori K; Saito M; Ebina M; Sato I; Maemondo M; Yamada-Okabe H; Kondo T; Sasano H
J Pathol; 2014 Oct; 234(2):277-88. PubMed ID: 24687913
[TBL] [Abstract][Full Text] [Related]
12. Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells.
Kim S; Park AK; Cho J
Biochem Biophys Res Commun; 2018 Sep; 503(2):710-714. PubMed ID: 29909007
[TBL] [Abstract][Full Text] [Related]
13. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
14. Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells.
Lin Y; Higashisaka K; Shintani T; Maki A; Hanamuro S; Haga Y; Maeda S; Tsujino H; Nagano K; Fujio Y; Tsutsumi Y
Sci Rep; 2020 Mar; 10(1):4748. PubMed ID: 32179851
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
[TBL] [Abstract][Full Text] [Related]
16. LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers.
Chen C; Liu WR; Zhang B; Zhang LM; Li CG; Liu C; Zhang H; Huo YS; Ma YC; Tian PF; Qi Q; Li JJ; Tang Z; Zhang ZF; Giaccone G; Yue DS; Wang CL
Cancer Lett; 2020 Aug; 486():58-70. PubMed ID: 32439420
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib and Trametinib in Patients With
Luo J; Makhnin A; Tobi Y; Ahn L; Hayes SA; Iqbal A; Ng K; Arcila ME; Riely GJ; Kris MG; Yu HA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250388
[TBL] [Abstract][Full Text] [Related]
18. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
[TBL] [Abstract][Full Text] [Related]
19. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.
Gong Y; Somwar R; Politi K; Balak M; Chmielecki J; Jiang X; Pao W
PLoS Med; 2007 Oct; 4(10):e294. PubMed ID: 17927446
[TBL] [Abstract][Full Text] [Related]
20. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Yoshida T; Song L; Bai Y; Kinose F; Li J; Ohaegbulam KC; Muñoz-Antonia T; Qu X; Eschrich S; Uramoto H; Tanaka F; Nasarre P; Gemmill RM; Roche J; Drabkin HA; Haura EB
PLoS One; 2016; 11(1):e0147344. PubMed ID: 26789630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
